edoxaban

Ligand id: 7575

Name: edoxaban

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 164.87
Molecular weight 547.18
XLogP 0.4
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
This drug was initially approved in Japan for the treatment of venous thromboembolism (VTE). Subsequently, in January 2015, the US FDA approved adoxaban to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation that is not caused by a heart valve problem and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already received anti-clotting therapy for five to ten days.
Mechanism Of Action and Pharmacodynamic Effects
Edoxaban acts as a direct factor Xa inhibitor. This family of drugs inhibits coagulation without using antithrombin as a mediator.